Bayesian estimation of etoposide pharmacokinetic parameters;Estimation bayesienne des parametres pharmacocinetiques de l'etoposide

Bulletin du Cancer

Volumn 84, Issue 7, 1997, Pages 699-703

  Evene, Eric ^a   Chatelut, Etienne ^b   Tranchand, Brigitte ^b   Canal, Pierre ^b   Lochon, Isabelle ^b   Iliadis, Athanassios ^c   Ardiet, Claude Joseph ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Bayesian estimation; Etoposide; Pharmacokinetics

Indexed keywords

ETOPOSIDE; ANTINEOPLASTIC AGENT;

ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CANCER CHEMOTHERAPY; DRUG EFFICACY; HUMAN; PHARMACODYNAMICS; ADULT; AGED; CHEMICAL MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; RESEARCH DESIGN;

EID: 0031181505     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aisner J, Lee EJ. Etoposide : current and future status. Cancer 1991 ; 67 : 215-9.
2. D'lncalci M, Farina P, Sessa C. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982 ; 7 : 141-5.
3. Minami H, Horio Y, Sakai S, Saka H, Shimokata K. Pharmacokinetics of an etoposide infused over three days : concomitant infusion with cisplatin. Jpn J Clin Oncol 1991 ; 21 : 400-5.
4. Pfluger KH, Hahn M, Holz JB. Pharmacokinetics of etoposide : correlation of pharmacokinetic parameters and clinical conditions. Cancer Chemother Pharmacol 1993 ; 31 : 350-6.
5. Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans WE. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 1984 ; 44 : 3109-13.
6. Bennett CL, Sinkule JA, Schilsky RL, Conley BA, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion etoposide patients with advanced cancer. Cancer Res 1990 ; 47 : 1952-6.
7. Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994 ; 34 : S69-S75.
8. Stewart CF. Use of etoposide in patients with organ dysfunction : pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994 ; 34 : S76-S83.
9. Karlsson MO, Port RE, Ratain MJ, Sheiner LB. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 1995 ; 57 : 325-34.
10. Desoize B, Marechal F, Cattan A. Corrélations entre la pharmacodynamie clinique et la pharmacocinétique clinique du cisplatine et de l'étoposide. Ann Biol Clin 1993 ; 51 : 125-8.
11. Joel Sp, Heap L, Robbins S, Clarke PI, Slevin ML. A limited sampling strategy for the calculation of etoposide pharmacokinetics (abstract]. Proc Am Soc Clin Oncol 1990 ; 9 : 260.
12. Strömgren AS, Sörensen BT, Jakobsen P, Jakobsen A. A limited sampling method for estimation of the etoposide area under curve. Cancer Chemother Pharmacol 1993 ; 32 : 226-30.
13. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters: II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981 ; 9 (5) : 635-51.
14. Sheiner LB, Rosenberg B, Melmon KL. Modeling of individual pharmacokinetics for computer-aided drugs dosage. Comput Biomed Res 1972 ; 5 : 441-59.
15. Bressolle F, Bologna C, Edno L, Bernard JC, Gomeni R, Sany J, Combe B. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol 1996 ; 49 : 285-92.
16. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, Gomeni R. Population pharmacokinetics in critically ill patients. Antimicrob Agents Chemother 1996 ; 40 : 1682-9.
17. Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR. A bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985 ; 37 : 349.
18. Hurley FS, Neil JJ. A comparison of a least squares regression, a bayesian, Chiou's and steady state clearance method of individualizing theophylline dosage. Clin Pharmacokinet 1988 ; 15 : 5.
19. Illiadis A, Bachir-Rabo M, Bruno R, Favre R. Bayesian estimation and prediction of clearance in high-dose methotrexate infusion. J Pharmacokinet Biopharm 1985 ; 13 : 101-15.
20. Sheiner LB, Halkin H, Peck C, Rosenberg B, Melmon KL. Improved computer-assisted digoxin therapy. A method using a feedback of measured serum digoxin concentration. Ann Intern Med 1975 ; 82 : 619-27.
21. Vinks AATMM, Mouton JW, Touw DJ, Heijerman HGM, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 1996 ; 40 : 1091-7.
22. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 ; 9 (4) : 503-12.
23. Cunningham D, McTaggart L, Soukop M, Cummings J, Forrest GJ, Stuart JFB. Etoposide : a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumour Pharmacother 1986 ; 3 : 95-9.
24. Illiadis A. Le logiciel APIS: adaptation de posologie, identification et simulation en pharmacocinétique clinique. Journées d'Informatique Médicale de Montpellier. Montpellier : Sauramps Medical 1988 ; 100-11.